疑难病杂志2012，Vol.11Issue(2)：86-88,3.DOI:10.3969/j.issn.1671-6450.2012.02.003
强化心肌病治疗对尿毒症性心肌病患者N末端脑钠肽前体及心脏腔室的影响
Strengthen cardiomyopathy drug therapy on NT-proBNP and cardiax chamber in patients with uremic cardiomyopathy
吴风富 1覃善都 1覃梓健2
作者信息
- 1. 530021,南宁,解放军303医院心血管科
- 2. 443002,湖北省宜昌,三峡大学医学院
- 折叠
摘要
Abstract
Objective To investigate the clinical effect of strengthen cardiomyopathy therapy on uremic cardiomyopa-thy with the change of the NT-proBNP and cardiac chamber. Methods 100 patients of uremic cardiomyopathy were divided into strengthen treatment group and conventional treatment group randomly, each group had 50 patients. In conventional treatment group, the hemodialysis was applied, and in strengthen treatment group, the drug therapy was applied on the basis of he-modialysis. The expression of NT-proBNP, the change of cardiac chamber and ejection fraction were detected and compared in both two groups. Results The result showed that the cardiac function was improved obviously in strengthen treatment group than that of in conventional treatment group, with the decline of the expression of NT-proBNP significantly( P <0. 05 ). The cardiac chamber size contraction and cardiac ejection fraction increase rate were improved significantly in strengthen treatment group than those of conventional treatment group( P < 0.05 ). The total effective rate was higher in strengthen treatment group ( 88.0% ) than that of conventional treatment group ( 72.7% , P <0.05 ). And no obvious adverse reactions was observed in both two groups. Conclusion It proved that adding the neuroendocrine medicine to the therapy of the patients with uremic myocardiopathy could improve the patients'cardiac function obviously, enhance the life quality and increase the life span.关键词
心肌病,尿毒症性/N末端脑钠肽前体/心脏腔室/强化心肌病治疗Key words
Cardiomyopathy,uremic/NT-proBNP/ Cardiac chamber/ Strengthen cardiomyopathy drug therapy引用本文复制引用
吴风富,覃善都,覃梓健..强化心肌病治疗对尿毒症性心肌病患者N末端脑钠肽前体及心脏腔室的影响[J].疑难病杂志,2012,11(2):86-88,3.
